Online inquiry

IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5441MR)

This product GTTS-WQ5441MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets tcdA gene. The antibody can be applied in Clostridium difficile infectious diarrhea research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq WP_009902072.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57299391
UniProt ID P16154
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5441MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10817MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ1775MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ4067MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ4731MR IVTScrip™ mRNA-Anti-IL21, BOS161721(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BOS161721
GTTS-WQ1380MR IVTScrip™ mRNA-Anti-IL1A&IL1B, ABT-981(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-981
GTTS-WQ13061MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ13622MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA R4930
GTTS-WQ6701MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DNIB0600A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW